NCT00333788View on ClinicalTrials.gov

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

233

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Crohn's Disease

Interventions

BIOLOGICAL

Certolizumab pegol (CDP870)

400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks

Trial Locations (65)

Unknown

Gainesville

Atlanta

Chicago

Indianapolis

Louisville

Baton Rouge

Lincoln

New York

Chapel Hill

Charleston

Cincinnati

Cleveland

Oklahoma City

Portland

Charleston

Germantown

Nashville

Houston

Seattle

Innsbruck

Vienna

Bonheiden

Brussels

Genk

Ghent

Leuven

Liège

Roeselare

Edmonton

Vancouver

London

Toronto

Calgary

Clichy

Lille

Nice

Paris

Pessac

Berlin

Hamburg

Herne

Kiel

Leipzig

Minden

Munich

München

Bologna

Milan

Padua

Palermo

Roma

Torino

Eindhoven

Heerlen

Barcelona

Madrid

Santiago de Compostela

Seville

Valencia

Stockholm

Bern

Lausanne

Bristol

London

Oxford

Sponsors

Lead Sponsor

All Listed Sponsors

lead

UCB Pharma

INDUSTRY

NCT00333788 - Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease | Biotech Hunter | Biotech Hunter